Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Propanc Biopharma Inc (OP: PPCB )

0.0006 UNCHANGED
Streaming Delayed Price Updated: 3:57 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0006
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0006
Today's Range 0.0006 - 0.0006
52wk Range 0.0002 - 0.0339
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)
From Propanc Biopharma, Inc.
Via Business Wire

Performance

YTD
N/A
N/A
1 Month
+50.00%
+50.00%
3 Month
+20.00%
+20.00%
6 Month
-64.71%
-64.71%
1 Year
-95.86%
-95.86%

More News

Read More
Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma, Inc. (PPCB) Featured in Virtual Coverage of the Sidoti & Company Micro-Cap Investor Conference
Via Investor Brand Network
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Provides Shareholder Update
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery Program
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery Program
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s PRP to Target 80 – 90% of Cancer Cases
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Believes PRP Reduced Toxicity Will Impact Cancer Patient Lives Significantly
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Offers a Novel Way to Stop Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.